AI Simulation on MIRA1a Showcases Significant
Potential Advantages Over Plant-Based Medical Marijuana Related to
Anxiety, Appetite and Cognition
BALTIMORE, Dec. 4, 2023
/PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
("MIRA" or the "Company"), an innovative pre-clinical-stage
pharmaceutical company focused on neurologic and neuropsychiatric
disorders, has released new data from artificial intelligence (AI)
simulations that show that, compared to plant-based medical
marijuana, there may be significant potential advantages to the
therapeutic potential of MIRA1a, such as its potential to offer a
superior anti-anxiety treatment, increased cognition and without
the increased appetite associated with THC.
The simulations on MIRA1a were conducted in conjunction with the
Company's strategic collaboration with InSilicoTrials, a company
specializing in leveraging AI and simulations to enhance drug and
medical device development.
In silico analysis is a computational technique that uses AI to
predict the interaction between drugs and their targets. This
innovative approach facilitates the virtual screening of compounds
and the assessment of their pharmacological profiles before
physical trials, expediting drug development and increasing the
precision of therapeutic targeting.
"The results of our AI analysis work with InSilicoTrial's
efforts continue to validate MIRA1a as a potential pharmaceutical
candidate within a multi-billion-dollar market to address the unmet
needs of millions with anxiety and cognition issues with
potentially fewer negative side effects than THC," said
Erez Aminov, Chief Executive Officer
of MIRA Pharmaceuticals. "Following positive results from recent
in vivo animal testing and research indicating MIRA1a's
potential therapeutic effects, without the common negative side
effects seen with THC even at high doses, we believe these targeted
studies with InSilicoTrials employing artificial intelligence and
machine learning further underscores MIRA1a's position as a
promising development in the evolution of neuropharmacological
therapies as we work towards the goal of filing an Investigational
New Drug ("IND") Application with the Food and Drug Administration
("FDA")."
Decoding MIRA1a's Potential: A Possible Breakthrough in
Anxiety, Appetite, and Cognition
Through meticulous computer-aided simulations, researchers have
uncovered MIRA1a's predicted ability to initiate a response at
three pivotal receptors in the brain— Serotonin 1a (5-HT1a),
Serotonin 2c (5-HT2c), and Dopamine D1 receptors. Third-party
studies indicate that THC has no predicted activity at any of these
three receptors, highlighting MIRA1a's apparent unique properties
and potential as an intervention for neurological disorders.
- Unlocking Anxiety Relief: 5-HT1a Receptor
Activation
The simulations suggest that MIRA1a's agonistic
action on the 5-HT1a receptor aligns with established anxiolytic
properties in medications like Buspirone and certain SSRIs. This
finding could potentially result in providing a new therapy for
anxiety disorder interventions by addressing disrupted signaling
associated with this receptor.
- Battling Appetite Concerns: 5-HT2c Receptor
Modulation
The in silico analysis reveals MIRA1a's
interaction with the 5-HT2c receptor, suggesting its potential to
avoid the appetite related side effects often linked to THC.
Drawing parallels with Lorcaserin, known for its FDA approved
appetite-suppressing effects, MIRA1a stands out as a potentially
viable solution for those seeking neuropharmacological relief from
anxiety and cognitive impairment without the side effect of an
increase in appetite that accompanies THC.
- Cognitive Enhancement: Dopamine D1 Receptor
Activation
MIRA1a's engagement with the Dopamine D1 receptor
suggests a potential pathway for cognitive enhancement. With the
potential to influence learning and memory, MIRA1a's activation of
the D1 receptor may pave the way for novel interventions in
disorders associated with cognitive impairment.
"In the groundbreaking field of neuropharmacology, artificial
intelligence and machine learnings have ushered in a new era of
drug discovery and analysis," said Adam
Kaplin, MD, Ph.D., President and Chief Scientific Officer of
MIRA Pharmaceuticals. "Through the lens of AI, one gains a more
complete demonstration of MIRA1a's potential properties at
receptors that are not affected by THC. MIRA1a is uniquely
positioned to potentially provide anti-anxiety effects, mitigate
THC's known side effects of increased appetite, and promote
enhanced cognition, making it an exceptional candidate for
addressing complex neuropsychiatric conditions."
Luca Emili, Chief Executive
Officer of InSilicoTrials, added, "Through this collaboration,
InSilicoTrials and MIRA Pharmaceuticals are on a mission to
optimize and de-risk drug development by using machine
learning-based tools. Leveraging our advanced in silico platform
and AI expertise, we contributed to enhance the development of
MIRA1a, demonstrating the immense potential of collaborative
innovation in the pharmaceutical sector."
For investors and industry leaders, MIRA1a represents not only a
potential scientific breakthrough but also a significant commercial
opportunity to meet the urgent need for additional
neuropharmacological therapies following clinical trials and
undergoing the FDA approval process.
About InSilicoTrials
InSilicoTrials is an emerging startup founded by a team of life
science, cybersecurity and digital innovation experts, which aims
to revolutionize Healthcare through an innovative digital
simulation platform. We specialize in leveraging AI and simulations
to enhance drug and medical device development. Using in silico
techniques, we analyze data to predict safety and efficacy of
potential compounds, aiding Pharma, MedTech companies, and
researchers in efficient, cost-effective advancement by minimizing
extensive clinical trials. InSilicoTrials' cloud-based platform
offers advanced tools for in silico trials analyses, facilitating
the integration of AI and simulation technology into development
workflows.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a
pre-clinical-stage pharmaceutical development company with two
neuroscience programs targeting a broad range of neurologic and
neuropsychiatric disorders. The Company's novel oral pharmaceutical
marijuana, MIRA1a, is currently under investigation for treating
adult patients suffering from anxiety and cognitive decline, often
associated with early-stage dementia. MIRA1a, if approved by the
FDA, could mark a significant advancement in addressing various
neuropsychiatric, inflammatory, and neurologic diseases and
disorders.
MIRA has an exclusive licensing agreement for Ketamir-2, a
unique, patent pending novel oral ketamine analog under
investigation to potentially deliver ultra-rapid antidepressant
effects, providing hope for individuals battling
treatment-resistant depression (TRD) and major depressive disorder
with suicidal ideation (MDSI).
The U.S. Drug Enforcement Administration (DEA)'s scientific
review of MIRA1a and Ketamir-2 concluded that neither would be
considered a controlled substance or listed chemical under the
Controlled Substances Act (CSA) and its governing regulations.
Additional information about the Company is available at:
www.mirapharmaceuticals.com.
Forward-Looking Statements
This press release may contain forward-looking statements about
MIRA Pharmaceuticals, Inc. ("MIRA," "we," "us," or "our"). In some
cases, you can identify forward-looking statements by terminology
such as "anticipate,' "believe," "contemplate," "continue,"
"could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will" or
"would," or the negative of these terms or other comparable
terminology. These forward-looking statements are subject to
numerous risks and uncertainties, many of which are beyond our
control, including risks and uncertainties regarding our ability to
develop and obtain regulatory approval for our product candidates,
Ketamir-2 and MIRA1a. These statements are only predictions and
involve known and unknown risks, uncertainties and other factors,
which may cause our actual results, levels of activity, performance
or achievements of and those of our industry to be materially
different from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. Some of these risks and uncertainties are identified in
our Registration Statement on Form S-1 filed with the SEC (File No.
333-273024) and in our other filings with the SEC, which are
available at www.sec.gov. You
should not place undue reliance on any forward-looking
statement. We undertake no obligation to update or revise publicly
any of the forward-looking statements after the date hereof to
conform the statements to actual results or changed expectations
except as required by law.
General Note
This press release discusses product candidates that are in
early stage pre-clinical development and have not yet been approved
for marketing by the U.S. Food and Drug Administration. No
representations are made as to the safety or effectiveness of these
product candidates for the uses for which they are being studied.
There is no assurance that either product candidate will proceed
through development or will receive FDA approval for marketing.
View original
content:https://www.prnewswire.com/news-releases/mira-pharmaceuticals-releases-breakthrough-data-from-artificial-intelligence-simulations-302004158.html
SOURCE MIRA Pharmaceuticals, Inc.